| Report Finds Over-the-Counter Drug for Heartburn, Acid Reflux as ...
WASHINGTON, Jan. 22 /PRNewswire-USNewswire/ -- A widely available nonprescription drug -- Prilosec OTC -- is as effective a treatment for heartburn and acid reflux disease as prescription drugs costing almost 10 times more, according to an analysis from Consumer Reports Best Buy Drugs, a public education project of Consumers Union. "Many people with heartburn and acid reflux could save $1,000 to $2,000 a year by taking an over-the-counter drug that's just as effective as high-priced prescription drugs," said Gail Shearer, director of the Consumer Reports Best Buy Drugs project. "These are dramatic savings, and illustrate why consumers should talk to their doctors about identifying effective, lower-cost medicines," Shearer added. The over-the-counter drug Prilosec costs $19 to $26 a month on average nationwide, and can be even cheaper at large discount stores.
TV's the best bet to get a good gig
On occasion, I've been known to make the oh-so-slightest critical comments about my friends and colleagues in broadcasting.
But with the defection of several local television personalities to the world of public/press relations - and the big-time money they're raking in - my thinking on this issue has, shall we say, evolved. I'm in.
TV baby! That's where it's at. This week we learned that KSFY anchor Mitch Krebs is the new spokesman for Gov. Mike Rounds.
That follows the much-ballyhooed jump by Jodi Schwan from KELO to Mayor Dave Munson's staff.
Those two job changes were big news because they went to work for high-profile chief executives in our state. But the Best Little City in America is littered with former TV people working in hospitals, nonprofits and business.
Time may be right for Abbott to sell TAP stake
The "atmosphere" may finally be right for Abbott Laboratories to finally sell its 50 percent stake in a Lake Forest drugmaker, says Abbott Chief Executive Miles White.
With Abbott shedding low-margin businesses to focus on higher growth, Wall Street is focusing on the next possible divestiture: Abbott's TAP Pharmaceutical Products Inc. venture with Japan's largest drugmaker, Takeda Pharmaceutical Co. of Osaka.
Abbott agreed last week to sell a large part of its diagnostic test-making business to General Electric Co. for $8.13 billion in cash. The deal is part of Abbott's ongoing effort to shed low-margin businesses and focus on higher growth drugs and medical devices.
White talked openly recently about TAP and Abbott's discussions with Takeda over unloading its 50 percent stake.
|
